Company Filing History:
Years Active: 2020-2024
Title: Chang Soo Yang: Innovator in GPCR Heteromer Inhibitors
Introduction
Chang Soo Yang is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of cancer research through his innovative work on G protein-coupled receptor (GPCR) heteromers. With a total of 2 patents, his inventions focus on developing inhibitors that target specific receptor interactions associated with cancer.
Latest Patents
Chang Soo Yang's latest patents include groundbreaking work on GPCR heteromer inhibitors. These inventions relate to inhibitors of CXC receptor 4 (CXCR4)-G protein-coupled receptor (GPCR) heteromers, which are associated with various cancers. His research highlights the functional heteromer formation between CXCR4 and other GPCRs, known as GPCRx. The co-stimulation of CXCR4 agonists and GPCRx agonists leads to enhanced signaling downstream of CXCR4. Furthermore, his inventions provide methods for using inhibitors that target the interacting GPCR partner of the CXCR4-GPCRx heteromer. This includes the development of heteromer-specific inhibitors and antibodies, which can be utilized in the diagnosis and therapy for cancer.
Career Highlights
Chang Soo Yang is currently associated with GPCR Therapeutics, Inc., where he continues to advance his research in the field of GPCR heteromers. His work has the potential to significantly impact cancer treatment strategies and improve patient outcomes.
Collaborations
He collaborates with notable colleagues, including DongSeung Seen and Eunhee Kim, who contribute to his research endeavors and help drive innovation in the field.
Conclusion
Chang Soo Yang is a key figure in the development of GPCR heteromer inhibitors, with a focus on cancer-related applications. His innovative patents and ongoing research hold promise for advancing therapeutic options in oncology.